Assessment of co-processed composites of Cissus-acacia and Cissus-guar gums as suspending agents in metronidazole benzoate suspension

2021 ◽  
Vol 9 (2) ◽  
Author(s):  
Kenneth Ugoeze ◽  
Harriet Uwhuetume Oyagiri
Author(s):  
Yonas Brhane

Carboxymethylated Plectranthus edulis, Vatke (P. edulis) [fam., Lamiaceae] starch was evaluated as a suspending agent in metronidazole benzoate suspensions in comparison with sodium carboxymethyl cellulose (NaCMC) at concentration range of 1-4% (w/v). The resulting suspensions were evaluated for their sedimentation volume (%), degree of flocculation, rheology, redispersibility, and dissolution rate. Stability studies were performed for 3 months. The apparent viscosities of the formulations prepared with carboxymethylated P. edulis starch at reaction condition E (CMPS-E) was significantly lower than that of NaCMC (p < 0.05). The flowability of the suspensions, at all concentration levels of the suspending agents, were in the order of CMPS-E > NaCMC. AT 1% concentrations, carboxymethylated P. edulis starch (76 ± 1.5%) provided significantly higher (p < 0.05) sedimentation volume than NaCMC (40 ± 1.5%). At 3% and 4%, both gave comparable sedimentation volume (100%). Potassium dihydrogen phosphate (KH2PO4) employed as a flocculating agent significantly increased (p < 0.05) the sedimentation volume of the suspensions prepared with carboxy-methylated P.edulis starch and NaCMC. The redispersibilities of CMPS-E was better than those of NaCMC. All suspensions showed a release of greater than 85% of drug within 1 h. The results of stability studies showed that all suspension formulations were stable. From the foregoing, it can be concluded that carboxymethylated P. edulis starch could be used as an alternative suspending agent.


2020 ◽  
Author(s):  
Mohammad Seyedhamzeh ◽  
Bahareh Farasati Far ◽  
Mehdi Shafiee Ardestani ◽  
Shahrzad Javanshir ◽  
Fatemeh Aliabadi ◽  
...  

Studies of coronavirus disease 2019 (COVID-19) as a current global health problem shown the initial plasma levels of most pro-inflammatory cytokines increased during the infection, which leads to patient countless complications. Previous studies also demonstrated that the metronidazole (MTZ) administration reduced related cytokines and improved treatment in patients. However, the effect of this drug on cytokines has not been determined. In the present study, the interaction of MTZ with cytokines was investigated using molecular docking as one of the principal methods in drug discovery and design. According to the obtained results, the IL12-metronidazole complex is more stable than other cytokines, and an increase in the surface and volume leads to prevent to bind to receptors. Moreover, ligand-based virtual screening of several libraries showed metronidazole phosphate, metronidazole benzoate, 1-[1-(2-Hydroxyethyl)-5- nitroimidazol-2-yl]-N-methylmethanimine oxide, acyclovir, and tetrahydrobiopterin (THB or BH4) like MTZ by changing the surface and volume prevents binding IL-12 to the receptor. Finally, the inhibition of the active sites of IL-12 occurred by modifying the position of the methyl and hydroxyl functional groups in MTZ. <br>


1993 ◽  
Vol 82 (10) ◽  
pp. 1006-1009 ◽  
Author(s):  
Mino R. Caira ◽  
Luigi R. Nassimbeni ◽  
Bosch Van Oudtshoorn

2021 ◽  
Vol 1 (3) ◽  
Author(s):  
Ramana Murthy RVV

Previously we prepared fracturing linear gel with fossil diesel, bio-diesel and also used suspending, anti-settling agents and emulsifiers. But through this research, a novel and efficient method for the preparation of linear gel directly mixed with water, guar gum and sodium acetate together instantly. In this instead of diesel, we used water and no need to mix anti-settling agents, suspending agents, emulsifiers that resulted in 30 viscosity linear gel. Ammonium persulphate or Ammonium peroxidisulphate and enzyme-G are used for oxidation purposes to break the gel gradually at a particular static temperature. The degradation pattern observed from the breaker test showed that a reduction in gel viscosity depends on time, temperature & breaker concentration. Observations from experiments revealed that a small concentration of breakers provides rapid break compared to oxidative breakers. This article, designing of fracturing fluids describes how to use the fluid's viscosity generated by the gelling agents like guar gum for CBM operations.


2019 ◽  
Vol 75 (5) ◽  
pp. 483-495 ◽  
Author(s):  
Yara Santiago de Oliveira ◽  
Wendell Saraiva Costa ◽  
Poliana Ferreira Borges ◽  
Maria Silmara Alves de Santana ◽  
Alejandro Pedro Ayala

The use of supramolecular synthons as a strategy to control crystalline structure is a crucial factor in developing new solid forms with physicochemical properties optimized by design. However, to achieve this objective, it is necessary to understand the intermolecular interactions in the context of crystal packing. The feasibility of a given synthon depends on its flexibility to combine the drug with a variety of coformers. In the present work, the imidazole–hydroxy synthon is investigated using as the target molecule benzoylmetronidazole [BZMD; systematic name 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl benzoate], whose imidazole group seems to be a suitable acceptor for hydrogen bonds. Thus, coformers with carboxylic acid and phenol groups were chosen. According to the availability of binding sites presented in the coformer, and considering the proposed synthon and hydrogen-bond complementarity as major factors, different drug–coformer stoichiometric ratios were explored (1:1, 2:1 and 3:1). Thirteen new solid forms (two salts and eleven cocrystals) were produced, namely BZMD–benzoic acid (1/1), C13H13N3O4·C7H6O2, BZMD–β-naphthol (1/1), C13H13N3O4·C10H8O, BZMD–4-methoxybenzoic acid (1/1), C13H13N3O4·C8H8O3, BZMD–3,5-dinitrobenzoic acid (1/1), C13H13N3O4·C7H4N2O6, BZMD–3-aminobenzoic acid (1/1), C13H13N3O4·C7H7NO2, BZMD–salicylic acid (1/1), C13H13N3O4·C7H6O3, BZMD–maleic acid (1/1) {as the salt 1-[2-(benzoyloxy)ethyl]-2-methyl-5-nitro-1H-imidazol-3-ium 3-carboxyprop-2-enoate}, C13H14N3O4 +·C4H3O4 −, BZMD–isophthalic acid (1/1), C13H13N3O4·C8H6O4, BZMD–resorcinol (2/1), 2C13H13N3O4·C6H6O2, BZMD–fumaric acid (2/1), C13H13N3O4·0.5C4H4O4, BZMD–malonic acid (2/1), 2C13H13N3O4·C3H2O4, BZMD–2,6-dihydroxybenzoic acid (1/1) {as the salt 1-[2-(benzoyloxy)ethyl]-2-methyl-5-nitro-1H-imidazol-3-ium 2,6-dihydroxybenzoate}, C13H14N3O4 +·C7H5O4 −, and BZMD–3,5-dihydroxybenzoic acid (3/1), 3C13H13N3O4·C7H6O4, and their crystalline structures elucidated, confirming the robustness of the selected synthon.


1990 ◽  
Vol 16 (12) ◽  
pp. 1893-1909 ◽  
Author(s):  
David Johnston ◽  
Martin R. Gray ◽  
Colin S. Reed ◽  
Frank W. Bonner ◽  
Nicholas H. Anderson

Sign in / Sign up

Export Citation Format

Share Document